CAR-T 세포 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2033년)

Persistence Market Research has recently released a comprehensive report on the worldwide CAR T-Cell Therapy Market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

• CAR T-Cell Therapy Market Size (2024E): USD 3.7 Bn
• Projected Market Value (2033F): USD 20.6 Bn
• Global Market Growth Rate (CAGR 2024 to 2033): 21.3%

CAR T-Cell Therapy Market - Report Scope:

CAR T-cell therapy represents a groundbreaking advancement in the treatment of certain cancers, offering personalized immunotherapy by modifying a patient's T-cells to target and destroy cancer cells. This therapy has shown remarkable efficacy, particularly in hematologic malignancies such as leukemia and lymphoma. The market for CAR T-cell therapy is driven by increasing incidences of cancer, ongoing research and development activities, and the growing adoption of precision medicine. This market caters to both commercial applications and ongoing clinical trials, with several CAR T-cell therapies already approved by regulatory bodies.

Market Growth Drivers:

The global CAR T-cell therapy market is propelled by several key factors, including the rising prevalence of cancer, which has increased the demand for more effective and targeted therapies. Continuous advancements in genetic engineering and cellular therapies are enabling the development of new CAR T-cell therapies with improved safety and efficacy profiles. Additionally, growing investments in research and clinical trials, coupled with favorable regulatory frameworks, are facilitating the approval and commercialization of novel CAR T-cell therapies, thereby boosting market growth.

Market Restraints:

Despite its potential, the CAR T-cell therapy market faces challenges related to high treatment costs and complex manufacturing processes. The therapy's high price point can be a significant barrier to accessibility, particularly in low- and middle-income countries. Furthermore, the intricate and time-consuming process of manufacturing CAR T-cells, which involves extracting, modifying, and reinfusing the patient's cells, can limit the scalability and widespread adoption of this therapy. Safety concerns, such as the risk of severe side effects like cytokine release syndrome (CRS), also pose challenges that need to be addressed to enhance patient outcomes.

Market Opportunities:

The CAR T-cell therapy market presents significant growth opportunities driven by advancements in technology, the expansion of indications beyond hematologic cancers, and the development of allogeneic CAR T-cell therapies, which offer the potential for off-the-shelf treatments. The increasing focus on precision medicine and personalized treatments is expected to drive the adoption of CAR T-cell therapies in the coming years. Strategic partnerships between biotech companies and research institutions, investment in next-generation CAR T-cell platforms, and the exploration of combination therapies are essential to capitalize on these emerging opportunities.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the CAR T-cell therapy market globally?
• Which cancer types and indications are leading the adoption of CAR T-cell therapy?
• How are technological advancements influencing the competitive landscape of the CAR T-cell therapy market?
• Who are the key players contributing to the CAR T-cell therapy market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global CAR T-cell therapy market?

Competitive Intelligence and Business Strategy:

Leading players in the global CAR T-cell therapy market, including Gilead Sciences, Novartis AG, and Bristol-Myers Squibb, focus on innovation, clinical trial expansions, and strategic collaborations to gain a competitive edge. These companies invest heavily in R&D to develop next-generation CAR T-cell therapies with enhanced safety profiles and broader therapeutic applications. Collaborations with academic institutions, biopharma companies, and regulatory agencies are crucial in facilitating clinical development and market access. Emphasis on addressing manufacturing challenges, expanding treatment indications, and improving patient outcomes is driving market growth and reinforcing the position of key players in the evolving CAR T-cell therapy landscape.

Key Companies Profiled:

• Novartis AG
• Gilead Sciences Inc.
• Celgene Corporation
• bluebird bio, Inc.

Car T-Cell Therapy Industry Research by Category

Product

• Yescarta (axicabtagene ciloleucel)
• Kymriah (tisagenlecleucel)
• JCAR017 (lisocabtagene maraleucel)
• bb2121

Indication

• Relapsed Large B-cell Lymphoma
• Acute Lymphoblastic Leukemia (ALL)
• Multiple Myeloma

End User

• Car T-Cell Therapy at Hospitals
• Car T-Cell Therapy at Cancer Treatment Centers

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage/Taxonomy
• 2.2. Market Definition/Scope

3. Key Success Factors

• 3.1. Iceberg Analysis
• 3.2. Revenue Opportunity Analysis
• 3.3. Parent Market Analysis
• 3.4. Pipeline Assessment
• 3.5. Potential Population Eligible for CAR T-cell Therapy, By Region
• 3.6. List of Authorized Treatment Centers in the U.S. & U.K.
• 3.7. Key Inclusion & Exclusion

4. Market Background

• 4.1. Macro-Economic Factors
  • 4.1.1. Global GDP Outlook
  • 4.1.2. Global Healthcare Expenditure Outlook
• 4.2. Forecast Factors - Relevance & Impact
  • 4.2.1. Increasing Availability of CAR T-cell Therapy
  • 4.2.2. Increasing Adoption of CAR T-cell Therapy
  • 4.2.3. Superior Product Efficacy
  • 4.2.4. Improving Reimbursement Scenario
  • 4.2.5. Collaboration among Pharmaceutical and Biopharmaceutical Companies
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities

5. COVID-19 Crisis Impact Analysis

• 5.1. Current COVID-19 Probable Future Impact
• 5.2. Current GDP Projection and Probable Impact
• 5.3. Current Economic Projection as compared to 2008 Economic analysis
• 5.4. COVID19 and Impact Analysis
  • 5.4.1. Revenue By Product
  • 5.4.2. Revenue By Indication
  • 5.4.3. Revenue By End User
  • 5.4.4. Revenue By Country

6. Global Car T cell Therapy Market Value (Size US$Mn) Analysis 2019-2023 and Forecast 2024-2033,

• 6.1. Historical Market Value (US$Mn) Analysis, 2019-2023
• 6.2. Current and Future Market Value (US$Mn) Projections, 2024-2033
  • 6.2.1. Y-o-Y Growth Trend Analysis
  • 6.2.2. Absolute $ Opportunity Analysis

7. Global Car T cell Therapy Market Value (Size US$Mn) Analysis 2019-2023 and Forecast 2024-2033,By Product

• 7.1. Introduction/Key Findings
• 7.2. Historical Market Value (US$Mn) Analysis, By Product, 2019-2023
• 7.3. Current and Future Market Value (US$Mn) Projections, By Product, 2024-2033
  • 7.3.1. Yescarta (axicabtagene ciloleucel)
  • 7.3.2. Kymriah (tisagenlecleucel)
  • 7.3.3. JCAR017 (lisocabtagene maraleucel)
  • 7.3.4. bb2121
• 7.4. Market Attractiveness By Product

8. Global Car T cell Therapy Market Value (Size US$Mn) Analysis 2019-2023 and Forecast 2024-2033,By Indication

• 8.1. Introduction/Key Findings
• 8.2. Historical Market Value (US$Mn) Analysis, By Indication, 2019-2023
• 8.3. Current and Future Market Value (US$Mn) Projections, By Indication, 2024-2033
  • 8.3.1. Relapsed Large B-cell Lymphoma
  • 8.3.2. Acute Lymphoblastic Leukemia (ALL)
  • 8.3.3. Multiple Myeloma
• 8.4. Market Attractiveness By Indication

9. Global Car T cell Therapy Market Value (Size US$Mn) Analysis 2019-2023 and Forecast 2024-2033,By End User

• 9.1. Introduction/Key Findings
• 9.2. Historical Market Value (US$Mn) Analysis, By End User, 2019-2023
• 9.3. Current and Future Market Value (US$Mn) Projections, By End User, 2024-2033
  • 9.3.1. Hospitals
  • 9.3.2. Cancer Treatment Centers
• 9.4. Market Attractiveness By End User

10. Global Car T cell Therapy Market Value (Size US$Mn) Analysis 2019-2023 and Forecast 2024-2033,By Region

• 10.1. Introduction/Key Findings
• 10.2. Historical Market Value (US$Mn) Analysis, By Region, 2019-2023
• 10.3. Current Market Size (US$Mn) Analysis and Forecast By Region, 2024-2033
  • 10.3.1. North America
  • 10.3.2. Latin America
  • 10.3.3. Europe
  • 10.3.4. South Asia
  • 10.3.5. East Asia
  • 10.3.6. Oceania
  • 10.3.7. Middle East & Africa
• 10.4. Market Attractiveness By Region

11. North America Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033

• 11.1. Introduction
• 11.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
• 11.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
  • 11.3.1. By Country
    • 11.3.1.1. U.S.
    • 11.3.1.2. Canada
  • 11.3.2. By Product
  • 11.3.3. By Indication
  • 11.3.4. By End User
• 11.4 Market Attractiveness Analysis

12. Latin America Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033

• 12.1. Introduction
• 12.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
• 12.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
  • 12.3.1. By Country
    • 12.3.1.1. Brazil
    • 12.3.1.2. Mexico
    • 12.3.1.3. Argentina
    • 12.3.1.4. Rest of Latin America
  • 12.3.2. By Product
  • 12.3.3. By Indication
  • 12.3.4. By End User
• 12.4. Market Attractiveness Analysis

13. Europe Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033

• 13.1. Introduction
• 13.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
• 13.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
  • 13.3.1. By Country
    • 13.3.1.1. U.K.
    • 13.3.1.2. Germany
    • 13.3.1.3. France
    • 13.3.1.4. Italy
    • 13.3.1.5. Spain
    • 13.3.1.6. Russia
    • 13.3.1.7. BENELUX
    • 13.3.1.8. Rest of Europe
  • 13.3.2. By Product
  • 13.3.3. By Indication
  • 13.3.4. By End User
• 13.4. Market Attractiveness Analysis

14. South Asia Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
• 14.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. India
    • 14.3.1.2. Thailand
    • 14.3.1.3. Indonesia
    • 14.3.1.4. Malaysia
    • 14.3.1.5. Rest of South Asia
  • 14.3.2. By Product
  • 14.3.3. By Indication
  • 14.3.4. By End User
• 14.4. Market Attractiveness Analysis

15. East Asia Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
• 15.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. China
    • 15.3.1.2. Japan
    • 15.3.1.3. South Korea
  • 15.3.2. By Product
  • 15.3.3. By Indication
  • 15.3.4. By End User
• 15.4. Market Attractiveness Analysis

16. Oceania Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
• 16.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. Australia
    • 16.3.1.2. New Zealand
  • 16.3.2. By Product
  • 16.3.3. By Indication
  • 16.3.4. By End User
• 16.4. Market Attractiveness Analysis

17. Middle East & Africa Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
• 17.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. Turkey
    • 17.3.1.2. South Africa
    • 17.3.1.3. GCC Countries
    • 17.3.1.4. Rest of Middle East & Africa
  • 17.3.2. By Product
  • 17.3.3. By Indication
  • 17.3.4. By End User
• 17.4. Market Attractiveness Analysis

18. Key and Emerging Countries Car T cell Therapy Market Analysis 2024-2033

• 18.1. U.S. Car T cell Therapy Market Analysis
  • 18.1.1. By Product
  • 18.1.2. By Indication
  • 18.1.3. By End User
• 18.2. Canada Car T cell Therapy Market Analysis
  • 18.2.1. By Product
  • 18.2.2. By Indication
  • 18.2.3. By End User
• 18.3. Brazil Car T cell Therapy Market Analysis
  • 18.3.1. By Product
  • 18.3.2. By Indication
  • 18.3.3. By End User
• 18.4. Mexico Car T cell Therapy Market Analysis
  • 18.4.1. By Product
  • 18.4.2. By Indication
  • 18.4.3. By End User
• 18.5. Argentina Car T cell Therapy Market Analysis
  • 18.5.1. By Product
  • 18.5.2. By Indication
  • 18.5.3. By End User
• 18.6. U.K. Car T cell Therapy Market Analysis
  • 18.6.1. By Product
  • 18.6.2. By Indication
  • 18.6.3. By End User
• 18.7. Germany Car T cell Therapy Market Analysis
  • 18.7.1. By Product
  • 18.7.2. By Indication
  • 18.7.3. By End User
• 18.8. France Car T cell Therapy Market Analysis
  • 18.8.1. By Product
  • 18.8.2. By Indication
  • 18.8.3. By End User
• 18.9. Italy Car T cell Therapy Market Analysis
  • 18.9.1. By Product
  • 18.9.2. By Indication
  • 18.9.3. By End User
• 18.10. Spain Car T cell Therapy Market Analysis
  • 18.10.1. By Product
  • 18.10.2. By Indication
  • 18.10.3. By End User
• 18.11. Russia Car T cell Therapy Market Analysis
  • 18.11.1. By Product
  • 18.11.2. By Indication
  • 18.11.3. By End User
• 18.12. BENELUX Car T cell Therapy Market Analysis
  • 18.12.1. By Product
  • 18.12.2. By Indication
  • 18.12.3. By End User
• 18.13. India Car T cell Therapy Market Analysis
  • 18.13.1. By Product
  • 18.13.2. By Indication
  • 18.13.3. By End User
• 18.14. ASEAN Car T cell Therapy Market Analysis
  • 18.14.1. By Product
  • 18.14.2. By Indication
  • 18.14.3. By End User
• 18.15. China Car T cell Therapy Market Analysis
  • 18.15.1. By Product
  • 18.15.2. By Indication
  • 18.15.3. By End User
• 18.16. Japan Car T cell Therapy Market Analysis
  • 18.16.1. By Product
  • 18.16.2. By Indication
  • 18.16.3. By End User
• 18.17. South Korea Car T cell Therapy Market Analysis
  • 18.17.1. By Product
  • 18.17.2. By Indication
  • 18.17.3. By End User
• 18.18. Australia Car T cell Therapy Market Analysis
  • 18.18.1. By Product
  • 18.18.2. By Indication
  • 18.18.3. By End User
• 18.19. New Zealand Car T cell Therapy Market Analysis
  • 18.19.1. By Product
  • 18.19.2. By Indication
  • 18.19.3. By End User
• 18.20. GCC Countries Car T cell Therapy Market Analysis
  • 18.20.1. By Product
  • 18.20.2. By Indication
  • 18.20.3. By End User
• 18.21. Turkey Car T cell Therapy Market Analysis
  • 18.21.1. By Product
  • 18.21.2. By Indication
  • 18.21.3. By End User
• 18.22. South Africa Car T cell Therapy Market Analysis
  • 18.22.1. By Product
  • 18.22.2. By Indication
  • 18.22.3. By End Users

19. Market Structure Analysis

• 19.1. Market Analysis By Tier of Companies
• 19.2. Market Share Analysis By Key Players
  • 19.2.1. Regional footprint of Players
  • 19.2.2. Service Footprint by players
  • 19.2.3. Channel Foot Print by Players

20. Competition Analysis

• 20.1. Competition Dashboard
• 20.2. Competition Deep Dive
  • 20.2.1. Novartis AG
    • 20.2.1.1. Overview
    • 20.2.1.2. Product Portfolio
    • 20.2.1.3. Profitability by Market Segments (Product /End User/Region)
    • 20.2.1.4. Sales Footprint
    • 20.2.1.5. Strategy Overview
      • 20.2.1.5.1. Marketing Strategy
      • 20.2.1.5.2. Service Strategy
      • 20.2.1.5.3. End User Strategy
  • 20.2.2. Gilead Sciences Inc.
    • 20.2.2.1. Overview
    • 20.2.2.2. Product Portfolio
    • 20.2.2.3. Profitability by Market Segments (Product /End User/Region)
    • 20.2.2.4. Sales Footprint
    • 20.2.2.5. Strategy Overview
      • 20.2.2.5.1. Marketing Strategy
      • 20.2.2.5.2. Service Strategy
      • 20.2.2.5.3. End User Strategy
  • 20.2.3. Celgene Corporation
    • 20.2.3.1. Overview
    • 20.2.3.2. Product Portfolio
    • 20.2.3.3. Profitability by Market Segments (Product /End User/Region)
    • 20.2.3.4. Sales Footprint
    • 20.2.3.5. Strategy Overview
      • 20.2.3.5.1. Marketing Strategy
      • 20.2.3.5.2. Service Strategy
      • 20.2.3.5.3. End User Strategy
  • 20.2.4. bluebird bio, Inc.
    • 20.2.4.1. Overview
    • 20.2.4.2. Product Portfolio
    • 20.2.4.3. Profitability by Market Segments (Product /End User/Region)
    • 20.2.4.4. Sales Footprint
    • 20.2.4.5. Strategy Overview
      • 20.2.4.5.1. Marketing Strategy
      • 20.2.4.5.2. Service Strategy
      • 20.2.4.5.3. End User Strategy

21. Assumptions & Acronyms

22. Research Methodology